Human immediate early response 2 (IER2) has been implicated in tumor cell motility and metastasis; however, the underlying mechanisms in hepatocellular carcinoma (HCC) metastasis remain to be clarified. In this study, we demonstrate that dysregulation of IER2 was shown in HCC clinical samples, and IER2 expression resulted in the promotion of cell migration and invasion in vitro, and HCC tumor growth and pulmonary metastasis in vivo. Moreover, we showed that IER2 expression altered assembly of the actin cytoskeleton rearrangement. Furthermore, MAPK and PI3K/Akt signaling pathways induced by IER2 were confirmed to be probably involved in regulating the activity of Rho GTPases, such as RhoA, Rac 1 and Cdc42. Collectively, our results indicated a significant role of IER2 in the HCC cell motility and metastasis through MAPK and PI3K/Akt signaling pathways to regulate the activity of Rho GTPases, thereby modulating actin cytoskeleton rearrangement, unveiling a novel mechanism of cell motility regulation induced by IER2.
Immediate early response 2 (IER2) is identified as a member of the immediate early response gene family, which is an important regulator of cellular response to stimuli such as stress and hormones [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Human IER2 encodes a 223-amino acid protein, which is a proline-, serine-and arginine-rich protein, and is only 76% of homology to the protein encoded by pip92, a homologous gene in mouse [2] . Evidence is accumulating that IER2 is a DNA-binding protein which seems to act as a transcriptional factor [6] , and is involved in various kinds of physiology, such as angiogenesis and cancer [11] [12] , although the mechanism involved is only partly understood.
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third leading cause of cancer-related deaths worldwide, and the vast majority of HCC-related deaths are caused by metastasis [13] [14] [15] . Thus, understanding and elucidating the cellular mechanisms that modula te metastasis is vital to the development of effective HCC therapies. Accumulating evidence has shown that the interaction between integrin and Rho-family GTPases (Rho GTPases), such as RhoA, Rac1 and Cdc42, regulates the motility of various cancer cells [16] , and that Rho GTPases are molecular switches that regulate actin cytoskeleton reorganization and further modulate a variety of dynamic cellular functions including cell migration and invasion [17] . We have previously demonstrated that IER2 regulates HCC cell adhesion and motility via integrin -mediated signaling pathway [18] . Although IER2 has been shown to play critical roles in tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients [12, 18] , nothing is known regarding its involvement in integrin/ Rho GTPases signaling pathway.
In the present study, we demonstrated that dysregulation of IER2 was shown in HCC tissues. We revealed a crucial role for dysregulation of IER2 in regulating cell migration and invasion in vitro and in HCC growth and metastasis in vivo. Furthermore, we demonstrated a significant role of IER2 in the HCC cell motility and metastasis through activation of Rho GTPases.
Materials and Methods
Cell lines and culture conditions. Human embryonic kidney (HEK) 293T cells, p urchased from Lentiviral production and infection. The preparation of lentiviral vectors and production of the lentiviruses encoding IER2, shRNA against IER2, and indicated control lentiviruses were generated, and the stable cell lines expressing control (Ctrl1), IER2 (OE IER2), control-shRNA (Ctrl2), or shRNA against IER2 (KD IER2) were established and verified by RT-qPCR and western blotting as previously described [18] .
RT-qPCR. Total RNA was isolated from the tissues and the cells with RNA Isolator Total RNA Extraction Reagent (VAZYME, Nanjing, China), and reverse-transcribed using HiScript 1st Strand cDNA Synthesis Kit (VAZYME, Nanjing, China) following the manufacturer`s instructions. The cDNA was subjected to real-time PCR using the SYBR Green qPCR system (Takara, Dalian, China)
according to the manufacturer's instruction with the following primers: IER2 forward Cell migration and invasion assay. For wound healing assay, cells were seeded onto 6-well culture plates and serum-starved overnight and grown to confluence. Wounds were made by scraping across the cell monolayer with sterile P200 pipette tips in the middle of each well. After removing the cell debris, the remaining cells were maintained in fresh DMEM supplemented with 1% FBS at 37 °C for 24 h. Wound closure was observed and photographed under an inverted microscope, and relative migration of cells was calculated. Transwell cell migration and invasion assays were performed as described previously [18] . In brief, cells were serum-starved overnight and then 2.5×10 4 cells were seeded in uncoated or Matrigel (BD Biosciences)-coated membrane of inserts with 8.0 m pores (6.5 mm, Corning, NY, USA) of the 24-well transwell, respectively, and then placed into the lower chamber filled with 600 µl of fresh DMEM supplemented with 10% FBS followed incubation at 37 °C for 24 h. The migrated or invaded cells on the lower surface of the inserts were fixed with methanol for 15 min, and stained with 0.1% crystal violet for 20 min, and counted from six random fields at 200× magnification per insert from triplicate wells. All experiments were performed in triplicate and repeated three times.
Immunofluorescence analysis. The cells seeded on sterile cover-slips in 24-well plates were fixed with 4% paraformaldehyde, permeabilized with 0.1% TritonX-100, blocked with Image-iT FX Signal Enhancer (Invitrogen), and then incubated with rhodamine-conjugated phalloidin (Sigma-Aldrich, USA) for 1 h at room temperature. After washing with PBST, the nuclei were counterstained with 0.5 µg/ml DAPI (Sigma-Aldrich, USA). Images were captured using a fluorescence microscope.
Rho GTPase activity assays. Rho GTPases activity was determined using the RhoA/Rac1/Cdc42 G-LISA Activation Assay Kits (Cytoskeleton Inc., Denver, CO, USA) according to the cells were grown to 70 80% confluence and lysed. Equalized protein extractions were distributed to a pre-coated plate, and then incubated with the antibod ies specific to RhoA, Rac1, or CDC42, followed by incubation with a HRP-conjugated secondary antibody. Active GTP-bound RhoA, Rac1, or CDC42 were detected with HRP detection reagent, and the absorbance was measured at 490 nm by using a microplate reader.
In vivo tumor growth and metastasis. Athymic nude mice (BALB/C-nu/nu, 6 
Results
Analysis the expression of IER2 in HCC tissues. We first analyzed the mRNA level of IER2 in clinical specimens from the TCGA database (https://genome-cancer.ucsc.edu). We found that IER2 mRNA is downregulated in HCC tumor tissues compared with matched non-tumor liver tissues 1E ). Furthermore, we have previously performed western blotting analysis to evaluate the expression of IER2 in a panel of HCC cell lines HepG2, SMMC7721, SK-HEP1 and MHCC97H
cells (four HCC cell lines with increasing spontaneous metastatic potential), and we demonstrated that higher level of IER2 was shown in SK-HEP1 and MHCC97H cells, which have high metastatic potential, and lower level of IER2 was observed in HepG2 and SMMC7721 cells, which have low metastatic potential [18] , suggesting that IER2 expression was positively correlated with the metastatic potential of the HCC cell lines. Therefore, we speculate that IER2 may serve function as a regulator in HCC.
IER2 regulated tumor growth and metastasis. To explore whether IER2 played a role in vivo tumor growth and metastasis, stably over-expressing and knocking down IER2 in MHCC97H cells were established and verified as previously described [18] . MHCC97H cells stably over-expressing IER2, knocking down IER2 and their corresponding control cells were subcutaneously injected into nude mice, respectively. Tumor bearing mice were sacrificed and the tumors were dissected at the end of the experiment. Compared to the indicated control group, injection of mice with MHCC97H cells stably over-expressing or knocking down IER2 resulted in obvious increase of tumor size and weight, especially in the group of cells over-expressing IER2 (Figures 2A-2C) .
Immunohistochemically staining and RT-qPCR verified that the IER2 over-expression and knockdown in the indicated tumor tissues ( Figures 2D, 2E ). We also examined the functional role of IER2 in vivo tumor metastasis using the tail vein metastasis models. MHCC97H cells stably over-expressing IER2, knocking down IER2 and their corresponding control cells were injected into the tail veins of nude mice, respectively. Twenty four days later, nude mice were sacrificed and the tumor metastasis were analyzed. We found that the number of the pulmonary nodules was significantly increased in mice injected with MHCC97H cells stably over-expressing IER2, compared to those injected with control ( Figure 2F ). H&E staining verified that the observed pulmonary nodules in over-expressing IER2 cells, some metastatic lesions were found in lung tissue compared with control group (Figure 2G ). Taken together, these results indicated that IER2 could regulate HCC growth and metastasis in vivo.
IER2 modulated the migration and invasion of HCC cells through regulating actin
cytoskeleton rearrange ment. In order to verify whether IER2 regulated the metastasis of HCC by influencing cell motility, we first examined IER2 functions in cell migration and invasiveness in vitro. MHCC97H cells with IER2 overexpression showed rapid wound closure in wound-healing assays, and their migration and invasion efficiency obviously increased in transwell assays compared with corresponding control cells, whereas knockdown of IER2 resulted in reduction of cell motility (Figure 3 ). Accordingly, we proposed that IER2 played a role in HCC cell invasiveness and metastasis. Considering that cellular motility is closely coupled with the protrusions of the leading edge of migrating cells (filopodia and lamellipodia), which is driven by assembly and disassembly of actin filaments [19] , we next investigated whether IER2 could regulate HCC cell motility through influencing actin cytoskeleton rearrangement by staining with phalloidin. We observed that MHCC97H cells stably over-expressing IER2 displayed broad ruffle and lamellipodia formation at the leading edge, which was responsible for actin polymerization to allow cell locomotion, whereas MHCC97H cells knocking down IER2 exhibited a thin or minimal lamellipodia along the free edge ( Figure 4A ). These findings clearly demonstrated that IER2
induced the migration and invasion of MHCC97H cells is correlated with the modulation of the lamellipodia formation or actin reorganization.
IER2-induced actin reorganization was associated with the Rho GTPases . Accumulating evidence implicates the members of the Rho family of small GTPases, such as RhoA, Rac1 a nd Cdc42, as key regulators of the actin cytoskeletal rearrangement in the process of tumor cell migration, invasion and metastasis [20] . To examine whether IER2-induced actin reorganization is associated with the Rho GTPases, we then determined the activity of RhoA, Rac1 and Cdc42 in MHCC97H cells by using the RhoA/Rac1/Cdc42 G-LISA Activation Assay. Compared with those in the indicated control cells, overexpression of IER2 enhanced the activity of both Rac1 and Cdc42 but reduced RhoA activity, and thereby promoted lamellipodia formation and cell migration, whereas IER2 knockdown showed a significant reduction of the activity of Rac1 and a slight but non-significant alteration of the activity of RhoA and Cdc42 in MHCC97H cells ( Figure 4B-4D) .
These results clearly indicated that IER2 modulates the activity of the Rho family of GTPases, which might be the major cause of IER2 in lamellipodia formation of motile protrusions, thus further control the migration and invasion of MHCC97H cells.
IER2 enhanced cell motility by activating the downstream signaling molecules. We have previously demonstrated that IER2 regulates HCC cell adhesion and motility via ITGB1-mediated signaling pathway [18] , which may trigger several downstream signaling pathways such as PI3K-Akt and MAPK (ERK, JNK and p38) to regulate the activity of the Rho family of GTPases, resulting in reorganization of the actin cytoskeleton [21] [22] . Thus, we further performed western blotting to explore whether IER2 expression regulated the PI3K/Akt and MAPK signaling pathways.
As shown in Figure 5 , 
Discussion
HCC is a poor prognosis tumor with a high frequency of relapse and metastasis, which is a complex cascade of events, including the migration and invasion of HCC cells. Therefore, a better knowledge about the mechanisms that regulate the processes of the migration and invasion is essential for the development of diagnostic markers and effective approaches to decrease HCC mortality. There is evidence showed that IER2 has some DNA binding ability and is involved in tumor cell motility and metastasis [6, 12, 18] , however, the underlying mechanisms in HCC metastasis remain elusive. In this study, we provided evidence that dysregulation of IER2 was shown in HCC clinical samples, and revealed a crucial role for dysregulation of IER2 in regulating cell migration and invasion in vitro and in HCC growth and metastasis in vivo. Furthermore, we demonstrated a significant role of IER2 in the HCC cell motility and metastasis through the activation of Rho family of GTPases, suggesting that IER2 may function as an importa nt regulator in HCC metastasis.
Although IER2 has been described to play roles in tumor cell motility and metastasis [12, 18] , and our previous study showed that the elevated expression of IER2 was positively correlated with the high metastatic potential of certain HCC cells [18] , IER2 initially exhibited dysregulation in the HCC tissues in the present study. As enhanced tumor cell motility always promote s cells metastasis, we first evaluated whether dysregulation of IER2 could also induce HCC growth and metastasis in vivo. We demonstrated that ectopic IER2 expression in MHCC97H cells promoted HCC tumor growth and metastasis in mice in vivo, whereas silencing IER2 expression in MHCC97H cells promoted HCC tumor growth but displayed non-significant alteration of tumor metastasis in mice.
Moreover, we also demonstrated that IER2 overexpression acquired an obvious increased ability for migration and invasion, underwent rearrangement of the actin cytoskeleton. Thus, these findings provide the evidence supporting the pro-metastatic function of IER2 in HCC.
The Rho family of GTPases, including Rho A, Rac1 and Cdc42, are important regulators of actin cytoskeleton dynamics that potentiate cell migration and invasion [20] [21] [22] [23] [24] . Generally, Rac1 and Cdc42 act at the leading edge of the cell to induce the formation of lamellipodia and cell polarization, respectively, to promote cell migration, whereas RhoA acts in the cell body to facilitate contraction [23] [24] [25] . In this study, we demonstrated that overexpression of IER2 increased the activity of both Rac1 and Cdc42 but reduced the activation of RhoA in MHCC97H cells, and thereby contributed to the formation of lamellipodia, leading to the promotion of cell migration and invasion. Interestingly, we also found a correlation between depletion of IER2 and Rac1 activity but not Cdc42 and RhoA activity in MHCC97H cells. Based on this evidence, we assumed that IER2 might be involved in regulating actin dynamics through Rho family GTPases and could thereby affect HCC motility.
Our previous study showed that IER2 increased HCC cell adhesion and motility through transcriptional regulation of ITGB1 and subsequently activating the ITGB1-FAK-Src-paxillin signal pathway [18] . As integrin-mediated signaling pathway may also function as critical mediators of the PI3K-Akt and MAPK signaling pathways to regulate the activation of Rho family of GTPases [21, 22, 26] , this prompted us to investigate whether IER2 can further modulate the downstream signaling events involving PI3K-Akt and MAPK (ERK, JNK and p38) pathways. In the present study, we demonstrated that IER2 overexpression significantly up-regulated the levels of the phosphorylation of p38, ERK and Akt, while IER2 knockdown resulted in down-regulation of the phosphorylation of ERK but up-regulation of the phosphorylation of p38. However, the mechanism by which IER2 affects PI3K-Akt and MAPK remains to be further explored. Taken together, our observations demonstrated that IER2-induced the activation of Rho GTPases in MHCC97H cells might be mediated, at least in part, by regulating the MAPK ERK and p38 and Akt signaling pathways, thereby regulating the migration and invasion of HCC cells.
In conclusion, we provided novel insight into the significance of IER2 expression in HCC, and revealed a crucial role of IER2 in HCC tumor growth and metastasis. Our findings showed that IER2 played an important role during HCC cell migration and invasion through MAPK and PI3K-Akt signaling pathways to regulate the activity of Rho GTPases, thereby modulating actin cytoskeleton rearrangement. Further study of the specific mechanism as to how IER2 aberrant expression impact the occurrence, malignant degree and metastasis of HCC is ongoing, however, the findings presented here may contribute to improve our understanding of IER2 function in HCC and may also be important for the development of novel HCC biomarkers. 
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